Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and associated with high response rates.
da Fonseca ARB, Justino CC, de Molla VC, Yamakawa PE, Rabelo IB, Arnold LM, Kelly RJ, Griffin M, Munir T, Hill A, Velloso EDRP, Dalessandro T, Risitano AM, Scheinberg P, Kulasekararaj AG, Arrais-Rodrigues C.
da Fonseca ARB, et al. Among authors: arrais rodrigues c.
Blood Adv. 2024 Dec 18:bloodadvances.2024014159. doi: 10.1182/bloodadvances.2024014159. Online ahead of print.
Blood Adv. 2024.
PMID: 39693508